vTv Therapeutics Inc.
VTVT · XNASCIK 1641489fmd_0WYDH86MX2J89VA7VJWRM98DX5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 12 | 3 | 6 | 4 | 2 | 0 | 1 | 0 |
| Research and development | 45 | 40 | 23 | 15 | 11 | 13 | 12 | 14 | 12 | 18 |
| Total operating expenses | 56 | 51 | 32 | 24 | 18 | 26 | 25 | 26 | 25 | 33 |
| Operating income | (55) | (51) | (20) | (21) | (12) | (22) | (23) | (26) | (24) | (33) |
| Interest expense | 0 | 3 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Other non-operating income (expense) | (0) | – | 0 | 0 | 0 | 2 | (4) | (1) | – | – |
| Income before taxes | (55) | (54) | (24) | (22) | (13) | (18) | (25) | (26) | (23) | (31) |
| Income tax expense | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (55) | (55) | (24) | (22) | (13) | (18) | (25) | (26) | (23) | (31) |
| Net income | (16) | (16) | (8) | (13) | (8) | (13) | (19) | (20) | (18) | (27) |
| Net income to common shareholders | (16) | (16) | (9) | (18) | (8) | (13) | (19) | (20) | (18) | (27) |